Medrx reported in its stock chatter that Growth Capital filed a correction to Change Report No. 6. The correction concerned historical acquisition and disposal quantities, and the date on which the reporting obligation arose was 17 July 2026.
Growth Capital Co., Ltd. publicly disclosed that it had corrected Change Report No. 6. The correction concerned errors in the historical acquisition and disposal quantities stated in Report No. 6, and the filer was Growth Capital Co., Ltd.
The earnings forecast for Medrx for the fiscal year ending December 2026 was disclosed, with revenue expected to rise sharply to ¥390 million, up 200.8% year on year. The relevant business is centered on the company's core technology as a drug-discovery company focused on transdermal formulations such as patches.
The summary of the second-quarter earnings report for the fiscal year ending December 2026 was also released. Revenue was ¥11 million, operating loss was ¥544 million, ordinary loss was ¥554 million, and the quarterly net loss attributable to owners of the parent was ¥551 million. No information on nighttime PTS trading was reported, and the earnings summary was presented as consolidated information under Japanese GAAP.
Some posts suggested that share price movements could be expected while the market awaits the signing of a sales licensing agreement, and attention remains focused on a market awaiting the next catalyst.